share_log

野村:重申中国生物制药“买入”评级 目标价降至6.16港元

Nomura: Reiterates China Biopharmaceutical's “Buy” Rating Target Price Reduced to HK$6.16

新浪港股 ·  Mar 15 04:58

According to a research report released by Nomura, the profit of China Biopharmaceuticals (01177) in the second half of last year is expected to achieve high growth on a low year-on-year basis, and the Group also expects more business development transactions, sale of non-core subsidiaries and new drug listings in the 2024 fiscal year. In addition, Zhongsheng Pharmaceutical's sales forecasts for the 2023 and 2024 fiscal years were lowered by 5.6% and 7.3%, respectively, while profit estimates were lowered by 12.2%, respectively. However, the bank reiterated its “buy” rating and the target price was reduced from HK$6.63 to HK$6.16.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment